Isoniazid-monoresistant tuberculosis in France: risk factors, treatment outcomes and adverse events

Isoniazid-resistant, rifampicin-susceptible tuberculosis (HR-TB) is the most prevalent form of drug-resistant TB worldwide (besides streptomycin resistance) with estimates rising up to 7% among new TB cases and to 8 to 11% among previously treated TB cases (World Health Organization, 2018; Dean et al., 2020). HR-TB is associated with a higher risk of acquiring further drug resistance and in particular of evolving towards multidrug-resistant TB (MDR-TB), defined by resistance to both isoniazid and rifampicin (Menzies et al., 2009; Jacobson et al., 2011; Gegia et al., 2012).

Source: International Journal of Infectious Diseases - April 3, 2021 Category: Infectious Diseases Authors: Marwa Bachir, Lorenzo Guglielmetti, Simone Tunesi, Typhaine Billard-Pomares, Sheila Chiesi, J érémy Jaffré, Hugo Langris, Valérie Pourcher, Frédéric Schramm, Nadine Lemaître, Jérôme Robert, on behalf of the Isoniazid Resistance Group Source Type: research